Compares prostate biopsy guided by PSMA PET/CT or MRI imaging
Tests imaging-guided prostate biopsy in men with low PSA and a prior negative biopsy.
Plain-language title generated from the registry record
Registry title: The Diagnostic Application of PSMAPET/MR in Patients Undergoing Secondary Prostate Puncture
Key facts
- Where
- Nanjing, ChinaSee the site
Where in China
- Nanjing First HospitalNanjing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nanjing First Hospital, Nanjing Medical University
- Trial code
- NCT06901492
- Record updated
- 30 March 2025
- Original description
The present study is designed to explore the value of targeted puncture guided by PSMA PET/CT or mpMRI in the diagnosis of patients with low PSA and initial negative prostate biopsyRead full original descriptionShow less
The Diagnostic Application of PSMA PET/MR in Patients with PSA <20 Ng/ml and Initial Negative Prostate Biopsy
The present study is designed to explore the value of targeted puncture guided by PSMA PET/CT or mpMRI in the diagnosis of patients with low PSA and initial negative prostate biopsy
Inclusion: Age ≥40 years, male; Serum PSA level 4-20 ng/mL; Serum PSA level 4-20 ng/mL; No contraindications to PSMA-PET/CT or MRI; Signed informed consent.
Exclusion: History of prostate surgery/radiotherapy; Coagulation disorders or active infection; Allergy to local anesthetics; Serum PSA >20 ng/mL; Acute prostatitis; Severe internal/external hemorrhoids, perianal, rectal, or gluteal lesions; Inability to tolerate the biopsy procedure.